Abstract
THE FUTURE of metabolic-dysfunction associated liver disease (MASLD) was discussed in an insightful session chaired by Hannes Hagström, Karolinska Institutet, Stockholm, Sweden; and Dina Tiniakos, National and Kapodistrian University of Athens, Greece, during the European Association for the Study of the Liver (EASL) Congress 2024, held in Milan, Italy from the 5ᵗʰ–8ᵗʰ June. Hot topics included the evolving role of hepatologists, novel treatments and biomarkers for MASLD, and the promise of AI in the field.
Reference7 articles.
1. Novo Nordisk. Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. NCT02970942. https://clinicaltrials.gov/study/NCT02970942.
2. Eli Lilly and Company. A study of tirzepatide (LY3298176) in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY-NASH). NCT04166773. https://clinicaltrials.gov/study/NCT04166773.
3. Boehringer Ingelheim. A study to test safety and efficacy of BI456906 in adults with non-alcoholic steatohepatitis (NASH) and fibrosis (F1-F3). NCT04771273. https://clinicaltrials.gov/study/NCT04771273.
4. Madrigal Pharmaceuticals, Inc. A Phase 3 study to evaluate the efficacy and safety of MGL-3196 (Resmetirom) in patients with NASH and fibrosis (MAESTRO-NASH). NCT03900429. https://clinicaltrials.gov/study/NCT03900429.
5. Inventiva Pharma. Phase 2b study in NASH to assess IVA337 (NATIVE). NCT03008070. https://clinicaltrials.gov/study/NCT03008070.